Fotonmedix Medical Laser Breakthrough Published in a Nature Sub-Journal:The World’s First Decoding of the Laser Therapy Mechanism for Asthma and Pneumonia
As 262 million asthma patients worldwide continue to suffer from drug dependence and side effects, and as conventional treatments remain trapped in the dilemma of “treating symptoms rather than causes,” the Fotonmedix R&D team has delivered a groundbreaking answer through innovative research. The team-led study on “980 nm Pulsed Near-Infrared Photobiomodulation Therapy for Allergic Asthma” has been successfully published in a prestigious Природа sub-journal, marking an original breakthrough by Chinese innovation in the field of laser medicine and opening a new frontier for non-pharmacological treatment of inflammation-related diseases.
Endorsement by a Top-Tier Journal
The “Gold Standard” of Global Scientific Recognition
As a highly influential international academic journal under the Природа portfolio, Scientific Reports is renowned for its rigorous peer-review process and its commitment to both cutting-edge innovation and clinical value. It serves as a global “touchstone” for scientific achievement. Research accepted by the journal must demonstrate both disruptive academic innovation and clear potential for industrial translation, making it a widely recognized benchmark across academia and industry. The inclusion of the Fotonmedix team’s research not only represents the highest level of recognition of the technology’s scientific validity, but also confirms that Chinese laser medical research has entered the world’s first tier.
Core Breakthrough
Deciphering the “Cellular Code” of Laser-Based Anti-Inflammation
For the first time, the Fotonmedix team has comprehensively revealed the core mechanisms by which 980 nm near-infrared light treats inflammation-related diseases at the cellular and molecular levels. In simple terms, the research identifies the key to laser-based “precision anti-inflammation”:
01 Precisely “Braking” the Inflammatory Response
The study found that 980 nm near-infrared light can directly act on pulmonary inflammatory lesions. By inhibiting the NF-κB inflammatory signaling pathway, it effectively “switches off” inflammation, reducing the production of key inflammatory cytokines such as IL-4, IL-5, and IL-13. These cytokines are the primary culprits behind airway thickening and excessive mucus secretion. Their reduction alleviates asthma symptoms such as wheezing and chest tightness at the root cause.
02 Blocking the Infiltration of “Inflammatory Cells”
Through in-depth cellular analysis, the team observed that лазерная терапия significantly reduces the infiltration of eosinophils and inflammatory monocytes into lung tissue. These cells are the core drivers of airway inflammation and tissue damage. Reducing their presence effectively prevents repeated lung tissue injury and lowers the risk of acute asthma exacerbations.
03 A Safe and Burden-Free “Green Therapy”
Unlike conventional drug-based treatments, this technology is non-invasive and achieves anti-inflammatory effects without pharmacological intervention. The study confirms that 980 nm near-infrared light can penetrate up to 15 cm into tissue, ensuring therapeutic efficacy for deep-seated inflammation while avoiding damage to healthy tissue. This effectively addresses the long-standing challenges of traditional therapies, such as significant side effects and the development of drug resistance.
Visualization of Key Outcomes: Treatment Logic at a Glance
The core value of this achievement lies in elevating laser therapy from an “experience-based application” на “precision-based treatment.” Rather than vague “irradiation for anti-inflammation,” it clearly defines scientific parameters such as photon frequency, photon dose, inflammatory cell types, anti-inflammatory mechanisms, and modes of action—providing clear and objective theoretical foundations for future clinical research.
A Hard-Core Team
Building an Innovation Moat Through Patents
Behind this top-tier publication lies years of dedicated effort by the Fotonmedix team in the field of laser medicine. As a leader in high-energy laser medicine in China, the team adheres to the philosophy of “science as the foundation, clinics as the guide,” constructing a formidable technological moat:
01 Industry-Leading Patent Portfolio
The team has filed 50+ domestic and international patents, including 20+ invention patents, covering core technologies such as multi-spectral laser frequency mixing, ultrafast laser technology, и intelligent dosage control systems. These patents not only support the practical implementation of the published research but also ensure the advanced performance and safety of clinical products.
02 Deep Integration of Industry, Academia, and Research
Fotonmedix has co-established China’s first High-Energy Laser Medical Laboratory с Tsinghua University и Tsinghua Haixia Research Institute, creating a full-chain research platform spanning basic research, technological breakthroughs, and clinical validation. The published study represents one of the laboratory’s core achievements, demonstrating efficient synergy between academic innovation and industrial translation.
03 Strong Clinical Validation
Related technology products have been deployed in 5,000+ medical institutions worldwide, including top-tier hospitals and specialized rehabilitation centers. They have served over one million patients in areas such as inflammation control, tissue repair, and postoperative rehabilitation, achieving a clinical effectiveness rate exceeding 95%. This vast body of real-world data provides solid scientific support and fully validates the technology’s clinical value.
Looking Ahead
Redefining a New Paradigm in Inflammation Treatment
The publication in a Природа sub-journal is not only a milestone for Fotonmedix, but also a new starting point for the global laser medical industry. The Fotonmedix team will continue to focus on inflammation-related diseases in human medicine, expanding near-infrared photon technology into areas such as osteoarthritis, chronic obstructive pulmonary disease (COPD), and prostatitis, allowing non-pharmacological and non-invasive laser therapy to benefit more patients.
From cellular analysis in the laboratory to real-world clinical applications, from patent strategy to top-tier journal recognition, Fotonmedix is leveraging the hard-core strength of Chinese innovation to break international technological barriers and define new global benchmarks for high-energy laser therapy—delivering to the world the dual power of Chinese scientific research and industrial integration.
FotonMedix
